Article Data

  • Views 806
  • Dowloads 130

Original Research

Open Access

Positive pelvic lymph node on [18F]-FDG PET is a prognostic factor in early-stage high-risk cervical cancer treated by radical hysterectomy and adjuvant chemoradiotherapy

  • D. Kim1
  • Y. K3,*,
  • W. Kim1
  • D. Park1
  • D. Suh2
  • K. Kim2
  • J. Lee3
  • H. Jeon3
  • J. Nam1

1Departments of Radiation Oncology, Busan

2Departments of Obstetrics and Gynecology, Biomedical Research Institute, Pusan National University Hospital and Pusan National University School of Medicine, Busan

3Department of Radiation Oncology, Pusan National University Yangsan Hospital and Pusan National University School of Medicine, Yangsan (Korea)

DOI: 10.31083/j.ejgo.2020.01.4815 Vol.41,Issue 1,February 2020 pp.42-47

Published: 15 February 2020

*Corresponding Author(s): Y. K E-mail:


Purpose: The prognostic value of [18F]-fluorodeoxyglucose positron emission tomography (FDG PET) in early-stage high-risk cervical cancer patients was evaluated. Materials and Methods: A total of 86 Stage IB or IIA cervical cancer patients with high risk factors (positive resection margin (RM), parametrial invasion (PI) or pelvic lymph node (PLN) metastasis) were retrospectively investigated. Results: There was a statistically significant decrease in recurrence-free survival (RFS) in patients with bulky tumor (p = 0.011), positive RM (p = 0.001), and PLN positivity on FDG PET (p = 0.012) in multivariate analyses. Independent prognostic factors for overall survival (OS) included non-squamous cell type (p = 0.005), bulky tumor (p = 0.020), and PLN positivity on FDG PET (p = 0.007). Patients with positive PLN on FDG PET had worse five-year RFS (62.0% vs. 85.0%, p = 0.013) and OS (68.7% vs. 89.5%, p = 0.011) rates than those with negative PLN uptake. Conclusion: PLN metastasis on FDG PET and bulky tumor were found to be statistically significant prognostic factors for both RFS and OS in early-stage high-risk cervical cancer patients.


Cervical cancer; High risk factors; Adjuvant chemoradiotherapy; FDG PET.

Cite and Share

D. Kim,Y. K,W. Kim,D. Park,D. Suh,K. Kim,J. Lee,H. Jeon,J. Nam. Positive pelvic lymph node on [18F]-FDG PET is a prognostic factor in early-stage high-risk cervical cancer treated by radical hysterectomy and adjuvant chemoradiotherapy. European Journal of Gynaecological Oncology. 2020. 41(1);42-47.


[1] Torre L.A., Bray F., Siegel R.L., Ferlay J., Lortet-Tieulent J., Jemal A.: “Global cancer statistics. 2012”. CA. Cancer. J. Clin., 2015, 65, 87.

[2] Mathew A., George P.S.: “Trends in incidence and mortality rates of squamous cell carcinoma and adenocarcinoma of cervix-worldwide”. Asian Pac. J. Cancer Prev., 2009, 10, 645.

[3] Inoue T., Okumura M.: “Prognostic significance of parametrial extension in patients with cervical carcinoma Stages IB, IIA, and IIB. A study of 628 cases treated by radical hysterectomy and lymphadenectomy with or without postoperative irradiation”. Cancer, 1984, 54, 1714.

[4] Toita T., Kato S., Niibe Y., Ohno T., Kazumoto T., Kodaira T., et al.: “Prospective multi-institutional study of definitive radiotherapy with high-dose-rate intracavitary brachytherapy in patients with nonbulky (<4-cm) stage I and II uterine cervical cancer (JAROG0401/JROSG04- 2)”. Int. J. Radiat. Oncol. Biol. Phys., 2012, 82, e49.

[5] Peters W.A., Liu P.Y,. Barrett R.J., Stock R.J., Monk B.J., Berek J.S., et al.: “Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix”. J. Clin. Oncol., 2000, 18, 1606.

[6] Kim D.H., Kim W.T., Bae J.S., Ki Y.K., Park D., Suh D.S., et al.: “Maximum standardized uptake value of pelvic lymph nodes in 18FFDG PET is a prognostic factor for para-aortic lymph node recurrence in pelvic node-positive cervical cancer treated with definitive chemoradiotherapy”. Int. J. Gynecol. Cancer, 2016, 26, 1274.

[7] Yang K., Park W., Huh S.J., Bae D.S., Kim B.G., Lee J.W.: “Clinical outcomes in patients treated with radiotherapy after surgery for cervical cancer”. Radiat. Oncol. J., 2017, 35, 39.

[8] Sedlis A., Bundy B.N., Rotman M.Z., Lentz S.S., Muderspach L.I., Zaino R.J.: “A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a Gynecologic Oncology Group Study”. Gynecol. Oncol., 1999, 73, 177.

[9] Eifel P.J., Burke T.W,. Morris M., Smith T.L.: “Adenocarcinoma as an independent risk factor for disease recurrence in patients with stage IB cervical carcinoma”. Gynecol. Oncol., 1995, 59, 38.

[10] Eifel . Morris M., Wharton J.T., Oswald M.J.: “The influence of tumor size and morphology on the outcome of patients with FIGO stage IB squamous cell carcinoma of the uterine cervix”. Int. J. Radiat. Oncol. Biol. Phys., 1994, 29, 9.

[11] Shibata K., Kajiyama H., Terauchi M., Yamamoto E., Ino K., Nawa A., et al.: “Feasibility and effectiveness of postoperative adjuvant concurrent chemoradiation therapy in Japanese patients with highrisk early-stage cancer of the uterine cervix”. Int. J. Clin. Oncol., 2008, 13, 233.

[12] Ryu H.S., Chun M., Chang K., Chang H., Lee J.: “Postoperative adjuvant concurrent chemoradiotherapy improves survival rates for high-risk, early stage cervical cancer patients”. Gynecol. Oncol., 2005, 96, 490.

[13] Okazawa M., Mabuchi S., Isohashi F., Suzuki O., Ohta Y., Fujita M., et al.: “The prognostic significance of multiple pelvic node metastases in cervical cancer patients treated with radical hysterectomy plus adjuvant chemoradiotherapy”. Int. J. Gynecol. Cancer, 2012, 22, 490.

[14] Polterauer S., Grimm C., Hofstetter G., Concin N., Natter C., Sturdza A., et al.: “Nomogram prediction for overall survival of patients diagnosed with cervical cancer”. Br. J. Cancer, 2012, 107, 918.

[15] Niibe Y., Onda T., Matsuo K., Inoue Y., Hayakawa K.: “Phase II Study of Concurrent Chemoradiotheapy Using Nedaplatin for Locally Advanced Uterine Cervical Carcinoma (KGROG0501): Final Results”. Anticancer. Res., 2017, 37, 6983.

[16] Kidd E.A., Siegel B.A., Dehdashti F., Grigsby P.W.: “Pelvic lymph node F-18 fluorodeoxyglucose uptake as a prognostic biomarker in newly diagnosed patients with locally advanced cervical cancer”. Cancer, 2010, 116, 1469.

[17] Onal C., Reyhan M., Parlak C., Guler O.C., Oymak E.: “Prognostic value of pretreatment 18F-fluorodeoxyglucose uptake in patients with cervical cancer treated with definitive chemoradiotherapy”. Int. J. Gynecol. Cancer., 2013, 23, 1104.

[18] Onal C., Guler O.C., Reyhan M., Yapar A.F.: “Prognostic value of 18Ffluorodeoxyglucose uptake in pelvic lymph nodes in patients with cervical cancer treated with definitive chemoradiotherapy”. Gynecol. Oncol., 2015, 137, 40.

[19] Chung H.H., Cheon G.J., Kang K.W., Kim J.W., Park N.H., Song Y.S.: “Preoperative PET/CT FDG standardized uptake value of pelvic lymph nodes as a significant prognostic factor in patients with uterine cervical cancer”. Eur. J. Nucl. Med. Mol. Imaging, 2014, 41, 674.

[20] Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration: “Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials”. J. Clin. Oncol., 2008, 26, 5802.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time